Growth Factor: Physiology and What Research Reports

What a growth factor is

A growth factor is a naturally occurring protein or peptide that carries an instruction between cells. It binds a specific receptor on a target cell's surface and triggers an internal signalling cascade that can change proliferation, survival, migration, differentiation or matrix production. The term is a functional category rather than a single molecule: dozens of distinct families exist, each with its own receptor, tissue distribution and biology.

Most growth factors act locally, released by one cell and sensed by neighbours, although several also circulate in blood at measurable concentrations. Signalling depends not only on how much factor is present but on where the receptor sits in the membrane; researchers have described the association of glycolipids and growth factor receptors within lipid raft microdomains as a determinant of receptor behaviour, and have published methods for isolating and analysing those domains (PMID 32770505).

Where growth factors are produced and what they do

Production sites vary by family. Nerve growth factor is associated with sensory and sympathetic neuron biology; hepatocyte growth factor is released by mesenchymal and endothelial cells; placental growth factor comes largely from placental tissue in pregnancy; insulin-like growth factor 1 is produced substantially by the liver under growth-hormone control; connective tissue growth factor is expressed in fibrotic and remodelling tissue.

How growth factors are measured and studied

The workhorse method is the immunoassay. A published protocol chapter described enzyme-linked immunosorbent assay (ELISA) approaches for monitoring nerve growth factor, including the practical considerations that determine whether a measurement is interpretable (PMID 28501999). Similar assay logic underlies clinical growth-factor testing; an article on placental growth factor testing framed it as a diagnostic opportunity in pregnancy care for patients with suspected preeclampsia (PMID 40818526).

Beyond measurement, three research strategies recur:

• Growth factor as biomarker. Researchers measured concentrations in blood and asked whether they track disease activity or stress, as in the report that circulating hepatocyte growth factor reflects activation of vascular repair (PMID 36061342).
• Growth factor as target. Studies block or neutralise a factor to test its causal role, as in the report that connective tissue growth factor inhibition enhanced cardiac repair and limited fibrosis after myocardial infarction (PMID 30847422).
• Growth factor as delivered agent. Because these proteins diffuse away and degrade quickly, a review examined gelatin matrices used for growth factor sequestration and controlled presentation in biomaterials (PMID 31954527).

Why the term matters in peptide research

Readers encounter "growth factor peptide" in several distinct senses, and the literature keeps them separate.

Full-length proteins versus short peptide mimics

Native growth factors are folded proteins, often glycosylated and disulfide-bonded, and are difficult to manufacture and stabilise. One approach is to design short synthetic sequences that reproduce part of the receptor-binding surface. A materials study described self-assembling peptides with insulin-like growth factor mimicry, combining a bioactive motif with a self-assembling scaffold (PMID 38145951). Such constructs are laboratory tools and investigational materials, not consumer products.

Endogenous factors as read-outs of other systems

IGF-1 is frequently measured because it integrates growth hormone signalling with nutritional and hepatic status. Researchers who examined insulin-like growth factor 1 and dehydroepiandrosterone levels in alcoholic liver cirrhosis used those measurements to characterise endocrine changes in liver disease (PMID 36262536).

Factors in reproductive and developmental biology

Growth factor signalling shapes tissue development. A review addressed growth factors and folliculogenesis in polycystic ovary patients, describing how local factors participate in follicle development (PMID 30754182).

What the literature reports across selected families

Nerve growth factor. A review in the neuroscience literature described NGF and pain mechanisms, covering how NGF signalling contributes to sensitisation of pain-sensing neurons (PMID 28441116). Separately, a French-language article examined nerve growth factor in pulmonary hypertension, extending NGF interest beyond pain into vascular disease (PMID 38461086).

Hepatocyte growth factor. Alongside the vascular-repair biomarker report (PMID 36061342), a case-oriented report discussed hepatocyte growth factor in the setting of primary systemic amyloidosis (PMID 34092767).

Placental growth factor. The Canadian obstetrics article argued that PlGF diagnostic testing represented an opportunity to change how suspected preeclampsia is assessed (PMID 40818526).

Growth Factor Signalling and Safety Signals: What Studies Report

The published record on growth factors is largely about physiology, measurement and targeting rather than about administering these molecules to healthy people, so the verified literature summarised here does not contain a human safety or dosing dataset. What it does show is that growth-factor pathways cut both ways. Signalling that supports repair in one context can drive unwanted remodelling in another: researchers reported that inhibiting connective tissue growth factor — not supplying it — enhanced cardiac repair and limited fibrosis after myocardial infarction (PMID 30847422). Similarly, nerve growth factor is described in the review literature as a driver of pain sensitisation rather than simply a restorative signal (PMID 28441116). Elevated circulating levels are not automatically favourable either; the study of circulating hepatocyte growth factor framed higher levels as a marker of stress-triggered vascular repair activation (PMID 36061342).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, symptom, laboratory result or treatment decision. Nothing here describes a protocol, and no dose is discussed because the verified sources cited do not report one.

Limits of the evidence

1. Assay values are method-dependent; the ELISA protocol chapter for nerve growth factor emphasised the technical steps that determine reliable monitoring (PMID 28501999).
2. Preclinical and materials findings, such as self-assembling peptides with insulin-like growth factor mimicry, were laboratory results and were not clinical outcomes (PMID 38145951).
3. Delivery remains a bottleneck, which is why researchers reviewed gelatin matrices for growth factor sequestration (PMID 31954527).

References

• Nerve Growth Factor and Pain Mechanisms (Annual Review of Neuroscience, 2017)
• ELISA for Monitoring Nerve Growth Factor (Methods in Molecular Biology, 2017)
• Nerve growth factor (NGF) in pulmonary hypertension (PH) (Revue des Maladies Respiratoires, 2024)
• Circulating Hepatocyte Growth Factor Reflects Activation of Vascular Repair in Response to Stress (JACC: Basic to Translational Science, 2022)
• Hepatocyte Growth Factor and Primary Systemic Amyloidosis (Journal of UOEH, 2021)
• Insulin-like growth factor 1 and dehydroepiandrosterone levels in alcoholic liver cirrhosis (JGH Open, 2022)
• Self-Assembling Peptides with Insulin-Like Growth Factor Mimicry (ACS Applied Materials & Interfaces, 2024)
• Placental Growth Factor Diagnostic Testing: An Opportunity to Transform Pregnancy Care for Patients With Suspected Preeclampsia in Canada (JOGC, 2025)
• Connective Tissue Growth Factor Inhibition Enhances Cardiac Repair and Limits Fibrosis After Myocardial Infarction (JACC: Basic to Translational Science, 2019)
• Association of Glycolipids and Growth Factor Receptors in Lipid Rafts (Methods in Molecular Biology, 2021)
• Gelatin Matrices for Growth Factor Sequestration (Trends in Biotechnology, 2020)
• Growth factors and folliculogenesis in polycystic ovary patients (Expert Review of Endocrinology & Metabolism, 2007)